New insights into the responder/nonresponder divide in rectal cancer: Damage-induced Type I IFNs dictate treatment efficacy and can be targeted to enhance radiotherapy
Abstract Rectal cancer ranks as the second leading cause of cancer-related deaths. Neoadjuvant therapy for rectal cancer patients often results in individuals that respond well to therapy and those that respond poorly, requiring life-altering excision surgery. It is inadequately understood what dict...
Main Authors: | Taylor P. Uccello, Maggie L. Lesch, Sarah A. Kintzel, Lauren B. Gradzewicz, Lillia Lamrous, Shawn P. Murphy, Fergal J. Fleming, Bradley N. Mills, Joseph D. Murphy, Angela Hughson, Gary Hannon, Jesse Garrett-Larsen, Haoming Qiu, Michael G. Drage, Jian Ye, Nicholas W. Gavras, David C. Keeley, Tanzy M. T. Love, Elizabeth A. Repasky, Edith M. Lord, David C. Linehan, Scott A. Gerber |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2023-07-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-023-05999-3 |
Similar Items
-
CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models
by: Jian Ye, et al.
Published: (2023-05-01) -
Responders and nonresponders to pharmacotherapy and allergen immunotherapy
by: Marek Jakalski, et al.
Published: (2019-12-01) -
Unit Nonrespondents in a Taiwan Telephone Survey
by: Kuang-hui Chen
Published: (2016-05-01) -
Sildenafil or Vardenafil Nonresponders’ Erectile Response to Tadalafil
by: Berat Cem Ozgur, et al.
Published: (2009-12-01) -
Troubleshooting a Nonresponder: Guidance for the Strength and Conditioning Coach
by: Benjamin H. Gleason, et al.
Published: (2021-06-01)